Psychedelic-Assisted Therapy: What We Know About Who Responds Best

Originally published: May 23, 2026 | Category: Clinical Research

Psychedelic-assisted therapy is the most talked-about development in mental health treatment since SSRIs. And for good reason. Early trials with psilocybin, MDMA, and ketamine have shown remarkable effect sizes for conditions that have historically been treatment-resistant. The public excitement is understandable, and your clients are likely hearing about these developments in the news, on podcasts, and from friends.

But as the field matures, a more nuanced question is emerging: who actually responds best to psychedelic-assisted therapy? Not everyone does. And understanding the predictors of response is essential both for clinicians considering referrals and for the field’s long-term credibility. A study published in Nature Mental Health in 2026 directly addressed this question by examining therapist-rated predictors of response. Here is what they found and what it means for you as a therapist.

The State of Psychedelic Research in 2026

Before we dive into the predictors, let us level-set on where the evidence stands. The landscape is evolving rapidly, and keeping current is essential for responsible clinical guidance.

Substance	Primary Indication	Evidence Stage	Legal Status (US)
MDMA	PTSD	Phase 3 completed; FDA decision pending	Schedule I (expanded access available)
Psilocybin	Treatment-resistant depression	Phase 2/3 ongoing	Schedule I (Oregon/Colorado state programs)
Ketamine	TRD, suicidal ideation	Meta-analysis confirming acute efficacy	Schedule III (off-label IV; FDA-approved esketamine)
LSD	Anxiety, depression	Phase 2	Schedule I (research only)
DMT/5-MeO-DMT	Depression, addiction	Phase 1/2	Schedule I (research only)
Ibogaine	Substance use disorders	Phase 1/2	Schedule I (research only)

Note: Legal status changes rapidly. Always verify current regulations in your jurisdiction. This table reflects US federal law as of May 2026.

Predictors of Response: What the Research Shows

The Nature Mental Health study and the broader literature point to three categories of predictors: patient factors, therapist factors, and setting or contextual factors. Each matters, and together they determine the likelihood of a positive therapeutic outcome.

1. Patient Factors

Psychological flexibility emerged as the strongest predictor of therapeutic response across multiple trials. Patients who scored higher on measures of psychological flexibility, the ability to stay present with difficult experiences without needing to control or avoid them, had significantly better outcomes. This makes intuitive sense: the psychedelic experience often involves confronting intense emotions, memories, and sensations. The ability to stay present with these experiences rather than fighting them or dissociating is a skill that predicts positive outcomes.

Readiness for change was another strong predictor. Patients who entered treatment with genuine motivation for psychological work, as opposed to expecting a chemical cure, showed larger and more durable improvements. This has direct implications for how we prepare clients for psychedelic therapy. Those who view it as a tool for active engagement in their own healing will benefit more than those who view it as a passive treatment.

Personality traits: Openness to experience, one of the Big Five personality traits, predicts both the quality of the acute psychedelic experience and longer-term therapeutic outcomes. Interestingly, the psychedelic experience itself tends to increase openness, creating a positive feedback loop. Clients who score higher on openness at baseline are more likely to have meaningful experiences and may need less preparatory work.

Prior experience with non-ordinary states: Patients who had prior experience with meditation, breathwork, or other altered states, even without psychedelics, tended to navigate the acute session with less anxiety and more therapeutic engagement. This does not mean clients without this experience cannot benefit, but they may need more preparation.

Contraindicated traits: Personal or family history of psychotic disorders, bipolar I disorder, and certain personality configurations including borderline and antisocial traits have been associated with higher risk of adverse reactions including prolonged psychological destabilization. Screening for these is non-negotiable.

Predictor	Direction	Strength of Evidence	Clinical Implication
Psychological flexibility	Positive	Strong	Screen with ACT-related measures; consider preparatory ACT work
Readiness for change	Positive	Strong	Assess motivation; preparatory sessions are essential
Openness to experience	Positive	Moderate	May be modifiable through preparation and mindfulness training
Prior non-ordinary state experience	Positive	Moderate	Not required but helpful; consider preparatory meditation
Strong social support	Positive	Moderate	Assess support network before referral
History of psychosis	Negative (contraindication)	Strong	Exclude carefully; thorough family history screening needed
Unstable medical conditions	Negative (contraindication)	Moderate	Medical clearance required before treatment
High trait neuroticism	Negative	Moderate	May need more preparatory sessions; higher support needs

2. Therapist Factors

The therapist’s role in psychedelic-assisted therapy is fundamentally different from standard psychotherapy. The therapist is not doing active intervention during the acute session. They are holding space, ensuring safety, and providing reassurance. The quality of this container matters enormously, and the research is beginning to identify specific therapist characteristics that predict better outcomes.

Therapeutic alliance is the same factor that predicts outcomes in standard therapy and is equally important in psychedelic-assisted therapy. Patients who reported stronger alliance with their therapists before and after the acute session had better outcomes. This is not surprising, but it is worth stating explicitly: the relationship matters, even with a powerful pharmacological intervention. The preparation phase is where this alliance is built.

Comfort with non-ordinary states: Therapists who are themselves comfortable with altered states, whether through training, personal experience, or supervised practicum, provide better care. Their anxiety does not transfer to the patient, and they are better equipped to handle difficult or emotionally intense sessions without becoming dysregulated themselves. This is a skill that can be developed through training and supervised practice.

Integration skills: The acute psychedelic session typically lasts four to eight hours. But the integration sessions that follow, helping the patient make meaning of the experience, may be where the therapeutic heavy lifting actually occurs. Strong integration skills include the ability to help clients construct coherent narratives from non-ordinary experiences, translate insights into behavioral change, and metabolize difficult or frightening experiences. Therapists who are trained in psychodynamic, existential, or narrative approaches may have particular strengths in this area.

Cultural competence: Patients come from diverse backgrounds with different relationships to altered states. Indigenous traditions have used plant medicines for millennia. Some patients may have family or cultural histories that include these traditions. Therapists need cultural competence to navigate these conversations respectfully and avoid appropriating or misrepresenting traditional practices.

3. Setting and Context

The set and setting framework popularized by Timothy Leary and now supported by data refers to the patient’s mindset and the physical or environmental context. This is not a soft variable in psychedelic therapy. It is arguably as important as the drug itself.

Physical environment: A comfortable, aesthetically pleasing room with temperature control, soft furnishings, and access to nature or nature imagery predicts better acute session outcomes. Clinical, sterile environments are associated with more difficult sessions and higher rates of adverse psychological reactions. The treatment room should feel safe, warm, and conducive to introspection.

Music: This is not incidental. Carefully curated playlists, typically instrumental, emotionally dynamic, and without lyrics, are part of the treatment protocol in most clinical trials. Music supports emotional processing and can guide the trajectory of the session. The choice of music is made by the treatment team based on the phase of the session and the patient’s needs. Research on therapeutic music for psychedelic sessions is an active area of study.

Preparation sessions: The number and quality of preparatory sessions strongly predicts outcomes. Most clinical protocols include two to four preparation sessions focused on building trust, setting intentions, practicing relaxation skills, and discussing what to expect. These sessions are not optional. They are an active ingredient of the treatment. Therapists who rush or minimize preparation may compromise outcomes.

The Integration Phase: Where Therapy Actually Happens

This is the part that most directly concerns you as a therapist. Even if you do not conduct psychedelic sessions, which require specific licensure, training, and legal framework, you can provide integration therapy. And it is arguably where the lasting change occurs. Integration therapy typically involves:

• Narrative construction: Helping the client make meaning of their experience in a way that connects to their life story and therapeutic goals
• Cognitive reframing: Translating insights from the session into actionable changes in thinking patterns and behavior
• Behavioral activation: Supporting the client in implementing new behaviors that align with their insights
• Relapse prevention: Preparing for the possible return of symptoms and developing a maintenance plan
• Processing difficult experiences: Some psychedelic experiences are challenging or frightening. Integration helps metabolize these and find meaning in them

Ethical Considerations for Therapists

As psychedelic therapy moves toward mainstream acceptance, therapists face a unique set of ethical challenges that deserve deliberate consideration.

Informed consent is fundamentally different in this context. Clients cannot fully understand what a psychedelic experience will be like until they have had one. The experience is ineffable, unpredictable, and deeply personal. Informed consent must therefore be an ongoing process, not a one-time form. It includes discussing the range of possible experiences, the uncertainty of outcomes, the limits of current evidence, and the risks including challenging psychological experiences and the possibility that symptoms may temporarily worsen.

The power dynamic is amplified. During the acute psychedelic session, clients are in an extremely vulnerable state. They cannot advocate for themselves. They cannot easily set boundaries. The therapist’s responsibility for maintaining safety and boundaries is magnified. Clear protocols for physical contact, verbal interaction, and emergency situations must be established before the session begins.

Dual relationships require careful navigation. Some training programs require therapists to undergo their own psychedelic experiences as part of the training. While this may have clinical benefits, it also creates a dual relationship where the therapist’s personal experience becomes part of the professional context. Therapists need to process their own experiences separately from their clinical work to maintain appropriate boundaries with clients.

Equity and access are serious concerns. Psychedelic therapy, if approved, will likely be expensive and inaccessible to many. Therapists have an ethical obligation to consider how their advocacy for these treatments interfaces with issues of healthcare equity. Who will have access? How do we ensure that marginalized communities, which often have the highest rates of trauma and treatment resistance, are not excluded from a promising new treatment?

How to Prepare Now

Whether you plan to become a psychedelic therapist or simply want to provide informed guidance to clients, here are concrete steps you can take starting today:

1. Complete a continuing education course on psychedelic science and therapy. Organizations like the Multidisciplinary Association for Psychedelic Studies, the Center for Psychedelic and Consciousness Research at Johns Hopkins, and the Psychedelic Research and Training Institute at Imperial College London offer accredited training for mental health professionals.
2. Learn the legal landscape in your jurisdiction. State laws regarding psychedelics are changing rapidly. Oregon and Colorado have legalized psilocybin therapy. Several other states are considering similar legislation. Know what is and is not legal where you practice.
3. Develop a referral network. Identify clinical trial sites, licensed psilocybin service centers in Oregon or Colorado, and ketamine clinics that follow evidence-based protocols. Having this information ready means you can guide clients efficiently when they ask.
4. Practice talking about non-ordinary states. Many therapists feel uncomfortable when clients describe unusual experiences. Get comfortable with language like “that sounds like it was meaningful for you,” “tell me more about what that was like,” and “how does that experience connect to what you are working on in therapy?”
5. Process your own relationship to altered states. Your personal beliefs, experiences, and biases about psychedelics will shape how you respond to clients. Explore these in supervision or personal therapy before they show up in your clinical work.

Practical Considerations for Therapists

Screening Clients for Referral

If a client asks you about psychedelic therapy, here is a practical screening framework with five questions you should answer before making a referral:

1. Is there a clear clinical indication? Psychedelic-assisted therapy is investigational treatment for specific conditions, not a general wellness intervention. It is being studied for PTSD, treatment-resistant depression, end-of-life anxiety, and substance use disorders. These are the conditions for which there is preliminary evidence.
2. Is there a contraindication? Personal or family history of psychotic disorders or bipolar I is the most important psychiatric red flag. Uncontrolled hypertension, certain cardiac conditions, seizure disorders, and pregnancy are common medical exclusions.
3. Is the client psychologically prepared? Assess psychological flexibility, readiness for change, and social support. Clients who score low on these may benefit from preparatory therapy before entering a psychedelic program.
4. Are they medically cleared? A thorough medical evaluation by a physician familiar with psychedelic therapy protocols is essential before proceeding.
5. Is the legal framework appropriate? Outside of clinical trials, FDA expanded access programs, and specific state programs in Oregon and Colorado, most psychedelics remain Schedule I substances. Referral to an illegal provider is not ethical, even if the client is motivated.

Integration as a Practice Area

You do not need to be a psychedelic therapist to offer integration therapy. If you are a licensed therapist with training in trauma-informed care, existential therapy, or narrative approaches, you have relevant skills. Consider taking a continuing education course on psychedelic integration, developing referral relationships with local psychedelic therapy programs, learning about the specific effects and after-effects of different substances, and building your comfort discussing non-ordinary states with clients. This is an emerging specialization that is likely to grow significantly in the coming years.

The Bottom Line

Psychedelic-assisted therapy is not a miracle cure, and it is not for everyone. The evidence increasingly shows that patient factors, particularly psychological flexibility and readiness for change, predict who benefits most. Therapist factors, especially therapeutic alliance and integration skills, matter enormously. And the setting, including the physical environment and preparation quality, shapes the outcome of the experience.

For therapists, the message is clear: start preparing now. Whether or not you ever conduct psychedelic sessions, your clients will ask about them. Understanding the evidence base, the legal landscape, and the predictors of response positions you to guide them toward safe, informed decisions. Those who dismiss psychedelic therapy out of hand, as well as those who embrace it uncritically, both miss the mark. The evidence-based path is to stay curious, stay informed, and help your clients navigate a rapidly changing treatment landscape with their eyes open.

---

References:

1. Carhart-Harris RL, et al. Psychedelic-assisted therapy: Predictors of response, a therapist-rated analysis. Nature Mental Health. 2026.
2. Goodwin GM, et al. Psilocybin for treatment-resistant depression: a Phase 2 double-blind randomized controlled trial. N Engl J Med. 2022;387:1637-1648.
3. Mitchell JM, et al. MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled Phase 3 study. Nat Med. 2023;29:2473-2483.
4. Bloomfield MAP, et al. Ketamine Infusions and Rapid Reduction of Suicidal and Depressive Symptoms. JAMA Psychiatry. 2026. PMID: 42090166
5. Jungaberle H, et al. Psychotherapy with psychedelics: predictors of therapeutic outcomes. Front Psychiatry. 2024;15:1284745.

Final Thoughts

The evidence for psychedelic-assisted therapy is promising but incomplete. As the Nature Mental Health study shows, patient factors, therapist factors, and setting all matter in determining who benefits. The field is moving from asking “does it work?” to asking “for whom does it work, under what conditions, and with what support?” These are the right questions. As therapists, our role is to stay informed, stay critical, and stay focused on the wellbeing of our clients rather than the hype surrounding a new treatment. The psychedelic renaissance will realize its potential only if it is built on a foundation of rigorous evidence, ethical practice, and genuine therapeutic skill.

---

This article is for educational purposes and does not constitute medical advice. Psychedelic-assisted therapy remains investigational for most indications. Clinicians should consult their jurisdiction’s regulations and ethical guidelines before making treatment recommendations.